Several preclinical and clinical studies have demonstrated the efficacy of these anti-IGF-1R mAbs in cancer therapy11, 12; however, challenging remains because some anti-IGF-1R mAbs failed to shown similar therapeutic effects in clinical trials, with hyperglycemia being one of the most frequent side effects13, 14, 15. This evidence concerns the gene IGF1R and Hyperglycemia.